Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ABBV vs MTNB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABBV Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ABBV Overall Winner 6-Pillar Tally: ABBV 6 – 0 MTNB Matrix Metrics: ABBV 9 – 1 MTNB

As of Nov 19, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABBV carries a Unified Composite Score of 53.5/100 (HOLD) at $283.54 (17.4x Forward P/E, 36.6% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. ABBV 53.5/100 HOLD), ABBV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (36.6% vs. 0.0% operating margin) and revenue trajectory (+10.3% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABBV vs MTNB
ABBV NYSE Head-to-Head Winner
Abbvie Inc.
Pharmaceutical Preparations
$283.54
-0.86% 1D
Market Cap $505.6B
TTM Revenue $66.0B
Forward P/E 17.4x
Beta / 30D Vol -0.02β · 20% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 42.0 Fund 46.0 Flow 72.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $290.41 · SMA50: $278.42
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (ABBV 6 – 0 MTNB)

Columns: Metric · ABBV · MTNB
1. Valuation Multiples ABBV
Forward P/E 17.4x N/M
Trailing P/E 49.1x N/M
PEG Ratio 0.59x N/M
EV / Revenue 8.7x N/M
2. Growth & Scale ABBV
Revenue Growth (YoY) +10.3% -100.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $66.0B N/A
Market Cap $505.6B $979,904
3. Profitability & Quality ABBV
Gross Margin 73.7% N/A
Operating Margin 36.6% 0.0%
Net Profit Margin 15.7% 0.0%
Return on Equity (ROE) 62.3% -147.5%
4. Balance Sheet & Cash Flow ABBV
Cash Generation (TTM) $18.9B N/A
Cash Flow Margin 28.6% N/A
Net Cash / Leverage $70.1B Net Debt $1.2M Net Cash
Dividend Yield 2.36% None (0.00%)
5. Options & Positioning ABBV
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 23.4% (12th %ile) N/A (N/A)
Put/Call OI Skew 0.57x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ABBV
OpEx & R&D Intensity 37.1% of Rev ($24.5B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABBV (9) vs MTNB (1)
Institutional Metric ABBV MTNB Criterion Row Edge
Market Capitalization
Scale
$505.6B $979,904 Larger Scale ABBV
Trailing P/E Ratio
Valuation
49.1x N/M Lower Multiple ABBV
Forward P/E Ratio
Valuation
17.4x N/M Lower Multiple ABBV
Revenue Growth (YoY)
Growth
+10.3% -100.0% Higher Growth ABBV
Operating Margin (TTM)
Profitability
36.6% 0.0% Higher Margin ABBV
Net Profit Margin
Profitability
15.7% 0.0% Higher Margin ABBV
Return on Equity (ROE)
Capital Efficiency
62.3% -147.5% Higher ROE ABBV
52-Week Range Position
Momentum
83% ($191–$303) 22% ($0–$3) Stronger Trend ABBV
Beta / 30D Volatility
Risk Regime
-0.02β · 20% Vol -7.20β · 147% Vol Lower Realized Risk ABBV
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 54.6 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
$66.0B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.59x PEG · 8.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$18.9B ($70.1B Net Debt) N/A ($1.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABBV +46.26 pp
ABBV: -0.44% · MTNB: -46.7%
3M Horizon MTNB +300.48 pp
ABBV: +7.01% · MTNB: +307.49%
6M Horizon ABBV +11.26 pp
ABBV: +32.19% · MTNB: +20.93%
1Y Horizon ABBV +52.59 pp
ABBV: +21.24% · MTNB: -31.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABBV Revenue MTNB Revenue ABBV Op. Margin MTNB Op. Margin Margin Leader
FY2018 $32.8B $0M 19.5% -12230.9% ABBV
FY2019 $33.3B $0M 39.0% -21067.4% ABBV
FY2020 $45.8B $0M 24.8% -15288.4% ABBV
FY2021 $56.2B $0M 31.9% -74954.5% ABBV
FY2022 $58.0B $0M 31.2% -771.3% ABBV
FY2023 $54.3B $0M 23.5% -2168.4% ABBV
FY2024 $56.3B N/A 16.2% N/A ABBV
FY2025 $61.2B N/A 24.6% N/A ABBV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABBV CONSOLIDATION
98d in phase · OBV DISTRIBUTION
Current IV 23.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ABBV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $294.55 · IV 27.4%

ABBV Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($29,455)

Compare $29,455 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 27.4% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $290 / $310 Bull Call Spread

Buy 1x $290C · Sell 1x $310C · 31d

Net Entry $900 Debit
T+5d @ +5% Move +$492 (+55%)
Max Risk / Buffer $900 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $280 / $260 Bull Put Spread

Sell 1x $280P · Buy 1x $260P · 31d

Net Entry $244 Credit
Max Credit / Yield +$244 (+13.9% RoM)
Max Risk / Buffer -5.8% Cushion ($1,756 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Asymmetric 1x1x1 ($300C + $290/$270P)

+1x 17d $290P · -1x 59d $270P · +1x 31d $300C

Net Entry $777 Debit
T+5d @ +5% Move +$603 (+13.0% RoM)
Max Risk / Buffer -8.3% Put Cushion ($4,633 Mgn)
5d Edge & Liquidity 7.3x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABBV Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $505.6B market capitalization and 36.6% operating margin.
OpEx & R&D Reinvestment 37.1% of Rev ($24.5B)
90D Engineering Disclosures 0 Published
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABBV vs MTNB Key Questions & Quantitative Answers

As of Nov 19, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABBV carries a Unified Composite Score of 53.5/100 (HOLD) at $283.54 (17.4x Forward P/E, 36.6% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. ABBV 53.5/100 HOLD), ABBV captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (36.6% vs. 0.0% operating margin) and revenue trajectory (+10.3% vs. -100.0% YoY).

ABBV leads the Growth & Scale pillar: ABBV posts +10.3% YoY revenue growth and N/A YoY earnings growth on $66.0B TTM revenue (73.7% gross margin, 36.6% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABBV cumulative revenue shifted +86.7% while MTNB shifted N/A. In operating R&D and SG&A reinvestment, ABBV deploys 37.1% of Rev ($24.5B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.

ABBV screens cheaper on headline valuation multiples. ABBV trades at 17.4x Forward P/E, 49.1x Trailing P/E, 0.59x PEG, and 8.7x EV/Revenue (28.6% FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABBV (62.3% ROE) versus MTNB (-147.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ABBV carries 23.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.02β · 20% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.